2024-516481-11-00招募中3 期
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
Exelixis Inc.33 个研究点 分布在 9 个国家目标入组 203 人开始时间: 2024年8月28日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 203
- 试验地点
- 33
- 主要终点
- Duration of PFS per RECIST 1.1 per BIRC
研究概览
简要总结
To evaluate the efficacy of cabozantinib in combination with atezolizumab versus second NHT (abiraterone or enzalutamide) in subjects with mCRPC who have previously received one and only one NHT (eg, abiraterone, apalutamide, darolutamide, or enzalutamide) to treat mCSPC, M0 CRPC, and/or mCRPC, and who have measurable visceral disease or measurable extrapelvic adenopathy
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Maintenance Phase
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Men with histologically or cytologically confirmed adenocarcinoma of the prostate.
- •Understanding and ability to comply with the protocol requirements, including scheduled visits, treatment plan, laboratory tests, and all otherstudy procedures. Evidence of a signed and dated ICF, indicating that the subject has been informed of all pertinent aspects of the study, prior to any screening assessments except those procedures performed as standard of care within the screening window.
- •Sexually active fertile subjects and their female partners must agree to use highly effective methods of contraception during the course of the study and for 4 months (16 weeks) after the last dose of cabozantinib in the experimental arm (cabozantinib + atezolizumab), 3 weeks after the last dose of abiraterone (control arm), or 3 months (12 weeks) after the last dose of enzalutamide (control arm). A barrier contraceptive method (eg, condom) is also required. In addition, men must agree not to donate sperm during these same periods.
- •Subjects must have had a rising PSA or radiographically progressed on their prior treatment with one, and only one, NHT (eg, abiraterone, apalutamide, darolutamide, or enzalutamide) for castration-sensitive locally advanced (T3 or T4) or metastatic castration-sensitive prostate cancer, M0 CRPC, and/or mCRPC.
- •Bilateral orchiectomy or ongoing ADT with a gonadotropin-releasing hormone (GnRH) agonist/antagonist (surgical or medical castration), with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening.
- •Measurable (extrapelvic soft tissue) metastatic disease per Investigator assessment as defined by at least one of the following: a. Measurable visceral (eg, adrenal, kidney, liver, lung, pancreas, spleen) disease per RECIST 1.1, OR b. Measurable extrapelvic adenopathy (ie, adenopathy above the aortic bifurcation).
- •Progressive disease at study entry as defined by at least one of the following two criteria: a. Prostate specific antigen (PSA) progression defined by a minimum of 2 rising PSA values from 3 or 4 most recent consecutive assessments with an interval of at least 7 days between assessments. b. Soft tissue disease progression (PD) in the opinion of the Investigator.
- •Age ≥ 18 years old or meeting country definition of adult, whichever is older, on the day of consent.
- •ECOG performance status score of 0 or
- •Recovery to baseline or ≤ Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy in the opinion of the Investigator.
- •Adequate organ and marrow function, based upon all of the following laboratory assessments from samples obtained within 21 days before randomization: a. Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 × 109/L) without granulocyte colony stimulating factor support within 2 weeks before screening laboratory sample collection. b. Platelets ≥ 100,000/mm3 (≥ 100 × 109/L) without transfusion within 2 weeks before screening laboratory sample collection. c. Hemoglobin ≥ 9 g/dL (≥ 90 g/L) without transfusion within 1 week before screening laboratory sample collection. d. Serum bilirubin ≤ 1.5 × upper limit of normal (ULN) e. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) both ≤ 3 × ULN. Subjects with known hepatic metastasis may enroll with serum ALT and AST both ≤ 5 × ULN. f. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 40 mL/min using the Cockcroft-Gault equation: (140 – age) × weight (kg)/(serum creatinine [mg/dL] × 72). g. Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.1 mg/mmol) or 24-hour urine protein < 1 g. h. Negative hepatitis B surface antigen (HBsAg) test i. Negative hepatitis C virus (HCV) antibody test, or positive HCV antibody test followed by a negative HCV RNA test and no ongoing anti- HCV therapy.
排除标准
- •Only evidence of metastasis is adenopathy below the aortic bifurcation, non measurable soft tissue (visceral or adenopathic) disease per RECIST 1.1, or bone-only disease.
- •Uncontrolled, significant intercurrent or recent illness that may impede analysis of safety data, including, but not limited to, the following: a. Cardiovascular and cardiac disorders b. Neuropsychiatric disorder likely to impede with ability to give informed consent or comply with protocol requirements c. GI disorders, including those affecting absorption or linked with a high risk of perforation or fistula formation: i. Tumors invading the GI tract, active peptic ulcer disease, acute pancreatitis, acute obstruction of the pancreatic or biliary duct, appendicitis, cholangitis, cholecystitis, diverticulitis, gastric outlet obstruction, or IBD ii. Abdominal fistula, bowel obstruction, GI perforation, or intraabdominal abscess within 6 months before randomization d. Hemoptysis of > 2.5 ml of red blood, clinically significant hematuria, hematemesis, coagulopathy, or other history of significant bleeding within 3 months before randomization e. Known cavitating pulmonary lesions or known endobronchial disease manifestation f. Lesions invading major pulmonary blood vessels g. Other clinically significant disorders, such as: i. Any active, known or suspected autoimmune disease ii. Any active infection requiring systemic treatment iii. Known HIV, AIDS-related illness iv. Active tuberculosis v. Known history of COVID-19 unless the subject has shown recovery from the disease at least 30 days prior to randomization vi. History of idiopathic pulmonary fibrosis, organizing pneumonia, druginduced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan vii. Serious non-healing wound/ulcer/bone fracture per Investigator judgment viii. Clinically significant malabsorption syndrome per Investigator judgment ix. Pharmacologically uncompensated, symptomatic hypothyroidism x. Moderate to severe hepatic impairment, known cirrhosis xi. Requirement for hemodialysis, peritoneal dialysis xii. History of solid organ transplantation xiii. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) - Patients with indwelling cathethers (e.g. PleurX®) are allowed
- •Major surgery within 4 weeks prior to randomization. Minor surgeries within 10 days prior to randomization. Subjects must have complete wound healing from major surgery or minor surgery before randomization. Subjects with clinically relevant ongoing problems from prior surgery are not eligible.
- •Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per ECG within 21 days before randomization.
- •Inability or refusal to swallow tablets or receive IV administration.
- •Previously identified allergy or hypersensitivity to components of the study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies. Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption are also excluded.
- •Any other active malignancy at time of randomization or diagnosis of another malignancy within 2 years prior to randomization that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, or carcinoma in situ of the breast.
- •Any prior systemic nonhormonal therapy initiated for the treatment of mCRPC.
- •Receipt of abiraterone within 1 week; cyproterone within 10 days; or receipt of flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen-receptor inhibitors within 2 weeks before randomization.
- •Radiation therapy within 4 weeks (2 weeks for bone metastases) prior to randomization. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
- •Known brain metastases (symptomatic or non-symptomatic) or cranial epidural disease unless adequately treated with radiotherapy, radiosurgery, or major surgery and clinically stable for at least 4 weeks prior to randomization.
- •Symptomatic or impending spinal cord compression or cauda equina syndrome.
- •Concomitant anticoagulation with oral anticoagulants including, but not limited to, platelet inhibitors (eg, clopidogrel or ticagrelor), warfarin, dabigatran, and betrixaban, except for those specified in the protocol.
- •Administration of a live, attenuated vaccine within 30 days prior to randomization. The use of inactivated vaccines for the prevention of infectious disease is permitted.
- •Systemic treatment with, or any condition requiring, either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to randomization. Subjects with brain metastases requiring systemic corticosteroid at any dose are not eligible.
结局指标
主要结局
Duration of PFS per RECIST 1.1 per BIRC
Duration of PFS per RECIST 1.1 per BIRC
Duration of OS
Duration of OS
次要结局
- ORR per RECIST 1.1 per BIRC
研究者
Exelixis Medical Affairs
Scientific
Exelixis Inc.
研究点 (33)
Loading locations...
相似试验
招募中
3 期
A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-small cell lung cancer2023-504209-35-00F. Hoffmann-La Roche AG207
招募中
3 期
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer2023-506576-27-00Janssen - Cilag International170
招募中
3 期
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"2023-508472-11-00NSABP Foundation Inc.978
已完成
2 期
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanced Therapies (bDMARD or tsDMARD)Rheumatoid Arthritis2023-504045-31-00Janssen - Cilag International55
招募中
3 期
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma2023-509711-83-00Bristol Myers Squibb International Corporation265